They suggested that the inhibition of the MEK1/2 pathway combined with chemotherapy not only enhances cell death in relapsed ALL but also overcomes human bone marrow stromal cell protection, which is imperative for therapeutic success in vivo. The gene discussed is MAP2K1; the disease is acute lymphoblastic leukemia.